Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Publications, UncategorizedBy m3supportNovember 23, 2017PubMed
Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Publications, UncategorizedBy m3supportNovember 15, 2017PubMed
MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia. Publications, UncategorizedBy m3supportOctober 3, 2017PubMed
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Publications, UncategorizedBy m3supportJuly 27, 2017PubMed
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Publications, UncategorizedBy m3supportJune 8, 2017PubMed
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. Publications, UncategorizedBy m3supportMay 19, 2017PubMed
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. PublicationsBy m3supportMay 3, 2017PubMed
Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. PublicationsBy m3supportMay 3, 2017PubMed
The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. PublicationsBy m3supportApril 18, 2017PubMed
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. PublicationsBy m3supportApril 10, 2017PubMed
